ONCAlert | Upfront Therapy for mRCC
Latest From
Nadofaragene Firadenovec Shows Durable Responses in NMIBC
7:30 PM, Mon February 17, 2020
FDA to Accelerate the Approval of Lurbinectedin in Small Cell Lung Cancer
7:24 PM, Mon February 17, 2020
Bruton Tyrosine Kinase Inhibitors Signal Promise in the Treatment of Chronic Lymphocytic Leukemia
7:00 PM, Mon February 17, 2020
Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung Cancers
4:58 PM, Mon February 17, 2020
Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung Cancers
4:58 PM, Mon February 17, 2020
Effects of SBRT Plus Nivolumab Result in Responses for Certain RCC Subgroups
3:40 PM, Mon February 17, 2020
Effects of SBRT Plus Nivolumab Result in Responses for Certain RCC Subgroups
3:40 PM, Mon February 17, 2020
Cabozantinib Plus ADT Shows Promise in Hormone-Naive Metastatic Prostate Cancer
2:30 PM, Mon February 17, 2020
Nivolumab Plus Sitravatinib Combo Impresses in Renal Cell Carcinoma
9:50 PM, Sun February 16, 2020
Pepinemab and Avelumab Combination Shows Positive Signs at Interim Analysis for NSCLC
3:00 PM, Sun February 16, 2020
